Bambusa Therapeutics, Inc. (BBTX): who owns it and who trades it
As of Nov 6, 2026, BBTX insiders reported 5 purchases worth $52.6M in the last 12 months. The largest buyer was Ra Capital Management, L.P. (Director), with $46.6M.
Latest filing Nov 6, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, BBTX insiders reported $52.6M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Ra Capital Management, L.P. +4 | Director | Purchase | 2.34M | $16.00 | $37.4M | Form 4 |
| Nov 2, 2026 | Ra Capital Management, L.P. +4 | Director | Purchase | 164,891 | $16.00 | $2.6M | Form 4 |
| Nov 2, 2026 | Helmut Wolfgang Jeggle | Director | Purchase | 375,000 | $16.00 | $6M | Form 4 |
| Oct 30, 2026 | Ra Capital Management, L.P. +4 | Director | Purchase | 189,909 | $14.23 | $2.7M | Form 4 |
| Oct 30, 2026 | Ra Capital Management, L.P. +4 | Director | Purchase | 263,911 | $14.92 | $3.9M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ra Capital Management, L.P. | Director, 10% owner | $46.6M | – | Nov 2, 2026 |
| Helmut Wolfgang Jeggle | Director, 10% owner | $6M | – | Nov 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
Bambusa Therapeutics company events
Bambusa Therapeutics filed 1 report on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 3, 2026.
- Nov 3, 2026RulesChanged its bylaws or articles. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named BBTX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 6, 2026 | RA Capital Management, L.P. | 13D | 14.6% |
| Nov 6, 2026 | RA Capital Management, L.P. | 13D | 14.6% |
| Nov 5, 2026 | ATHOS KG | 13G | 9.0% |
| Nov 5, 2026 | ATHOS KG | 13G | 9.0% |
Questions about Bambusa Therapeutics, Inc. (BBTX) stock
Are BBTX insiders buying or selling?
In the last 12 months, BBTX insiders reported 5 open-market purchases worth $52.6M and no sales. The latest trade was on Nov 2, 2026. See every trade.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.